Get started
Caribou Biosciences, Inc.Caribou Biosciences, Inc.Caribou Biosciences, Inc.

Caribou Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CRBU chart


Full chart

CRBU upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪153.03 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.65 USD
Net income (FY)
‪−102.07 M‬ USD
Revenue (FY)
‪34.48 M‬ USD
Shares float
‪79.18 M‬
Beta (1Y)
3.22

Employees


Employees (FY)
158
Change (1Y)
+21 +15.33%
Revenue / Employee (1Y)
‪218.21 K‬ USD
Net income / Employee (1Y)
‪−646.01 K‬ USD

About Caribou Biosciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Rachel E. Haurwitz
Website
cariboubio.com
Headquarters
Berkeley
Founded
2011
FIGI
BBG008G28LJ5
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CRBU news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CRBU is 1.69 USD — it has decreased by −5.59% in the past 24 hours. Watch Caribou Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Caribou Biosciences, Inc. stocks are traded under the ticker CRBU.
CRBU stock has fallen by −10.11% compared to the previous week, the month change is a −14.65% fall, over the last year Caribou Biosciences, Inc. has showed a −72.74% decrease.
We've gathered analysts' opinions on Caribou Biosciences, Inc. future price: according to them, CRBU price has a max estimate of 26.00 USD and a min estimate of 3.00 USD. Watch CRBU chart and read a more detailed Caribou Biosciences, Inc. stock forecast: see what analysts think of Caribou Biosciences, Inc. and suggest that you do with its stocks.
CRBU reached its all-time high on Sep 7, 2021 with the price of 32.65 USD, and its all-time low was 1.50 USD and was reached on Jul 5, 2024. View more price dynamics on CRBU chart.
See other stocks reaching their highest and lowest prices.
CRBU stock is 9.39% volatile and has beta coefficient of 3.22. Track Caribou Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Caribou Biosciences, Inc. there?
Today Caribou Biosciences, Inc. has the market capitalization of ‪153.03 M‬, it has decreased by −7.73% over the last week.
Yes, you can track Caribou Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Caribou Biosciences, Inc. is going to release the next earnings report on Mar 24, 2025. Keep track of upcoming events with our Earnings Calendar.
CRBU earnings for the last quarter are −0.38 USD per share, whereas the estimation was −0.45 USD resulting in a 15.47% surprise. The estimated earnings for the next quarter are −0.42 USD per share. See more details about Caribou Biosciences, Inc. earnings.
Caribou Biosciences, Inc. revenue for the last quarter amounts to ‪2.02 M‬ USD, despite the estimated figure of ‪3.08 M‬ USD. In the next quarter, revenue is expected to reach ‪2.11 M‬ USD.
CRBU net income for the last quarter is ‪−34.68 M‬ USD, while the quarter before that showed ‪−37.70 M‬ USD of net income which accounts for 7.99% change. Track more Caribou Biosciences, Inc. financial stats to get the full picture.
No, CRBU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 158.00 employees. See our rating of the largest employees — is Caribou Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Caribou Biosciences, Inc. EBITDA is ‪−160.47 M‬ USD, and current EBITDA margin is −326.40%. See more stats in Caribou Biosciences, Inc. financial statements.
Like other stocks, CRBU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Caribou Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Caribou Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Caribou Biosciences, Inc. stock shows the sell signal. See more of Caribou Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.